Onco360 names new chief executive

NEW YORK — Onco360, one of the nation’s largest independent providers of oncology pharmacy services, on Monday announced that Paul Jardina was named president and CEO.

 

“We are confident that Paul is the right leader to take Onco360 forward," said Greg Weishar, CEO of PharMerica, a signficant investor in Onco360. "His deep experience in healthcare and oncology make him the ideal CEO for Onco360. We are confident that, under his leadership, Onco360 will continue to fulfill its mission of transforming oncology pharmacy, now and in the future.”

 

Jardina has more than 20 years of healthcare industry experience as an executive in oncology and physician services. Most recently he served as president and CEO of U.S. Physiatry, a physician services company focused on physical medicine and rehabilitation in the post-acute continuum. Jardina has served in various leadership positions for U.S. Oncology (now McKesson Specialty Health), leading key business lines including oncology specialty pharmacy, drug distribution and radiation and imaging. In his role at U.S. Oncology, Jardina was instrumental in the development and growth of the company’s pharmaceutical service lines and its transition to an open market provider of oncology pharmaceutical services.

 

Burt Zweigenhaft will continue to serve as the company’s vice chairman and chief strategy officer. In this capacity, Zweigenhaft will focus on key strategic initiatives and business development to further support the company’s growth strategy.